• Report Adverse Event or Product Quality Complaint
  • Global Site
AstraZeneca Medical Information
  • Prescribing Information
  • Resources
    • Congress Library
    • Our Pipeline
    • AZ Clinical Trials
    • Externally Sponsored Scientific Research
  • Connect
    • Send MIR
    • Give Feedback

Search Medical Information

American Society of Nephrology - Kidney Week 2024

October 23 - 27, 2024

  1. LOKELMA (Sodium zirconium cyclosilicate)
  2. Chronic Kidney Disease
  3. Albuminuria
  4. FARXIGA (dapagliflozin)

pdf

Hyperkalemia-Related HRU Associated with Short-Term vs. Long-Term SZC Therapy in Patients with ESKD: The GALVANIZE Outcome study

pdf

Updated Design and Status of CONTINUITY: a Phase 4 Study of Continued Post-Discharge Sodium Zirconium Cyclosilicate in CKD

PDF

Effects of 3.0 mEq/L [K+] Dialysate with Sodium Zirconium Cyclosilicate (SZC) Versus 2.0 mEq/L [K+] Dialysate Without SZC on Cardiac Arrhythmia Rates

pdf

Hyperkalemia Treatment Strategies by Specialty in the TRACK Study: Interim Analysis

pdf

Evaluating the Clinical, Socioeconomic, and Environmental Impact of Guideline-directed Therapy in the US: an IMPACT CKD Analysis

html

Pediatric and Adult Kidneys Have Largely Similar Gene Expression in CKD and Non-CKD

html

Effects of Zibotentan Alone and in Combination with Dapagliflozin on Fluid Retention in Patients with CKD

html

Application of eGFR Thresholds as End Point Components in a Kidney Hierarchical Composite End Point

html

A Phase 2b Dose-Finding Study to Evaluate Effects of Balcinrenone/Dapagliflozin vs. Dapagliflozin in Patients With CKD and Albuminuria

PDF

Effect of Baxdrostat on Albuminuria in Treatment-resistant Hypertension

html

Effects of Dapagliflozin on Sodium Excretion and Blood Pressure in Patients with Type 2 Diabetes and CKD during Standardized Sodium Intake

html

Benefits of Dapagliflozin in Slowing eGFR Decline in Patients With Different Rates of eGFR Loss

html

Differences in Plasma Proteomic Profiles Between Patients With and Without Type 2 Diabetes and Chronic Kidney Disease: New Insights From DAPA-CKD

Need Help?

Contact Us

Send MIR

Submit a Medical Information Request

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

AstraZeneca Logo

This platform is provided as service to healthcare professionals by AstraZeneca Philippines, for medical educational purposes only.

©2024 AstraZeneca. All rights reserved.

PH-10554.

Last Updated 5/24

Contact Us

About Us

AstraZeneca.com

Survey Feedback

Privacy Notice

Legal Notice

Cookie Notice

Global Site

Report Adverse Event or Product Quality Complaint

Privacy NoticeLegal NoticeCookie Notice

Welcome to AstraZeneca Philippines Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the Philippines, for medical educational purposes only. AstraZeneca does not engage in the promotion of unregistered products or unapproved indications. The dissemination of this information may be subject to different medical and regulatory requirements in other countries

Are you a healthcare professional practicing in the Philippines?

No